What is it about?
In this pre-clinical study, we developed a novel approach (XDeath) by computational technology to screen new potential therapeutic targets for prostate cancer treatment. Interestingly, we identified a novel co-target, Plk1 and DNMT3a and validated the efficacy of co-inhibition of these two targets preclinically. The results showed that co-inhibition of Plk1 and DNMT3a significantly inhibited prostate cancer, providing evidence for translational study in clinic in the future.
Photo by National Cancer Institute on Unsplash
Why is it important?
A novel bioinformatic tool, XDeath was developed and applied to identify the novel targets for advanced prostate cancer for the first time. Subsequent series of experiments proved the promising of the combination treatments targeting Plk1 and DNMT3a pre-clinically. This study for the first time translates the findings generated by bioinformatics to pre-clinical studies and finally possibly in clinic.
Read the Original
This page is a summary of: Co‐Targeting Plk1 and DNMT3a in Advanced Prostate Cancer, Advanced Science, May 2021, Wiley, DOI: 10.1002/advs.202101458.
You can read the full text:
The following have contributed to this page